1 / 26

Hypercalcemia

Hypercalcemia. Case. 56 Y O F with generalized body pain for 1 day Also decreased PO intake Expressive aphasia due to CVA, cannot give further history PMH to de discussed later… PE: Vitals stable Moderate respiratory distress Somnolent but arousable Breath sounds only in R chest.

kapila
Download Presentation

Hypercalcemia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hypercalcemia

  2. Case • 56 Y O F with generalized body pain for 1 day • Also decreased PO intake • Expressive aphasia due to CVA, cannot give further history • PMH to de discussed later… • PE: • Vitals stable • Moderate respiratory distress • Somnolent but arousable • Breath sounds only in R chest

  3. Case, Continued • Labs: • Chem: 138/3.5/94/33/40/0.5 <114 – baseline BUN 7 • Ca 19.8 – 11.9 one week prior • CXR: complete opacification of L hemi-thorax. Volume loss, scarring and bronchiectasis in R lung • Next: What’s the first test you would order? • And what’s the diagnosis?

  4. Answers • PTH < 3 when repeat Ca 18.6 • History of NSCLS, squamous cell carcinoma, with intrabronchial invasion Important concepts in endocrine: 1- Two labs values are better than one; 3 is even better! 2- Timing 3- Inappropriately “normal” values

  5. Synthesis and Metabolism of Vitamin D in the Regulation of Calcium, Phosphorus, and Bone Metabolism. Holick MF. N Engl J Med 2007;357:266-281.

  6. Diagnostic Work Up PTH PTH-independent • Hypercalcemia of Malignancy • Vit D Intoxication • Granulomatous Disease • Hyperthyroidism • Vit A Intoxication • Adrenal Insufficiency • Milk-Alkali Syndrome • Thiazide Diuretics • Immobilization PTH-dependent • Primary Hyperparathyroidism • Familial HypocalciuricHypercalcemia • LithuimToxocity • Tertiary Hyperparathyroidism

  7. Why is PTH so important?

  8. General Rules • PHPT is at least twice as common as all other causes combined • Specially if pt seems well, hyperCa was found incidentally or is mild, stable or known to be of long duration • More than 90% of pts referred to endocrine have PHPT • Among ill or hospitalized pts, malignancy is the cause in more than 50% of cases • Confirm elevated Ca levels by repeating test and checking ionized Ca • History, PE, prior lab values, ….

  9. Primary Hyperparathyroidism • Primary abnormality of parathyroid tissue • Inappropriate secretion of PTH • What is appropriatehypersecretion of PTH in response to hypocalcemia? • Excessive PTH  • Increased renal Ca reabsorption • Phosphaturia • 1,25-OH2-Vit D synthesis • Bone resorption

  10. Primary Hyperparathyroidism • Etiology • One or more parathyroid adenomas (75-80%) • Diffuse hyperplasia of all glands (20%) • Parathyroid carcinoma (1-2%) • “Classic” manifestations • Bone: increased resorption • Renal: recurrent Ca stones, nephrocalcinosis, impaired concentrating ability, renal failure • GI: nausea, vomiting, constipation, abd pain, pancreatitis • Neuropsychiatric symptoms *

  11. “Contemporary” PHPT • Many pts are incidentally found, asymptomatic • Some have nl Ca and elevated PTH, found during work up of osteopenia • Natural course variable: bone loss, kidney disease, mortality • Management: observation vs. surgery

  12. Hypercalcemia of Malignancy • Most malignancies produce hyperCa only when far advanced • Pts usually die 1-2 months after hypercalcemia is discovered • Polydipsia, polyuria, constipation, nausea, vomiting, but especially dramatic changes in mental status • Mechanism • Local osteolytichypercalcemia: bone mets, most often in MM and breast cancer • Humoralhypercalcemia of malignancy: mediated by PTHrP, mimics all actions of PTH. Squamous cell cancers (lung, H&N, esophagus, cervix), breast cancer, RCC, bladder.

  13. Vit D Intoxication • Needs ingestion of about 100,000 IU of vit D per day • In US most often Iatrogenic • Hypercalcemia can be severe and prolonged (fat stores) • 25-OH-Vit D levels dramatically elevated • 1,25-OH2-Vit D normal or even low due to down regulation of renal 1α-hydroxylase by low PTH levels

  14. Granulomatous Disease • Sarcoidosis, TB, fungal infections, HIV-related PCP infection, Crohn’s disease • Unregulated production of active Vit D by macrophages • Pts unusually sensitive to vit D an can become hypercalcemic after exposure to ultraviolet light, or oral vit D intake

  15. Misc. Causes • Hyperthyroidism • Ca rarely >11 • Direct action of thyroid hormone to promote bone resorption • Vit A Intoxication • Requires ingestion of > 10x RDA (5000 IU/d) • Also Accutane (acne) and Retin-A (acute promyelocytic leukemia) • Adrenal Insufficiency • Thiazide Diuretics: in PHPT, sarcoidosis, excessive Ca intake

  16. Misc. Causes • Milk-Alkali syndrome • Hypercalcemia, metabolic alkalosis, renal failure • First described when milk and Na bicarb were used to treat PUD • Now seen with increasing use of Ca bicarb for PUD and osteoporosis • Immobilization • Spinal cord injury or excessive casting • Increased bone resorption • Peak Ca in 4 week, can last up to one year

  17. Management • Severe hypercalcemia > 14 mg/dl • Unusual in PHPT, unless a secondary mechanism is present • Dehydration from nausea, vomiting, diuretics • Immobilization • Large PO calcium intake • Severe acute hypercalcemia usually result of malignancy • Should we treat?

  18. Treatment: 1, 2, 3, … • Correct Intravascular volume depletion: NS 2-4 lit/d • Discontinue diuretics • +/_ furoemide • Bisphosphonates: first choice in management of severe hypercalcemia caused by osteolytic bone resorption • Not in milk-alkali syndrome • Ca decreases within 24 h, reaches nadir within 1 week • Use half the dose in moderate renal insufficiency (GFR>30) • Effect lasts 1 week to several months

  19. Treatment • Calcitonin: inhibits osteoclast function • Use with bisphosphonates for more rapid onset of action (a few hours) • Ca decreases by 1-2 mg/dl • Effect lasts a few days • Steroids: PO or IV • Consider early in Vit D mediated hypercalcemia, including granulomatous disease and lymphoma

  20. Treatment

  21. Follow Up • Ca repeated, 18.6 with PTH < 3 • PTHrP 55 (15-27) • 25-OH-Vit D and 1,25-OH2-Vit D <8 • IV hydration • Calcitonin 200 IU q 12 (Ca 17.6 after 1st dose) • Pamidronate 60mg IV infusion • 48 hours after admission Ca 12.9 • Transferred to pall care, expired 6 d after admission

  22. Case 1 • 49 yo F with laryngeal Ca s/p laryngectomy/chemo and RT with resultant hypothyroidism and hypoparathyroidism on replacement p/w weakness • Ca 15.6 • PTH < 3 • Cr 1.3 (baseline 0.8) • CO2 36 • Dx?

  23. Case 2 • 74 Y o M with colorectal Ca, dementia, dependant on ADL’sp/w AMS • Ca 14.2 – Hgb 9 – Cr 5.1 • PTH 21.4 • SPEP: no M spike, UPEP not sent • PTHrP 23 • 25-OH-Vit D 35.7, 1,25-OH2-Vit D 16 • Dx? • Ca 9.8 after hydration

  24. Case 3 • 84 Y O F with Ehlers-Danlos syndrome, professor of pediatric neurology at Einstein p/w AMS • Ca 16.2 • PTH<3 • SPEP, UPEP negative • 25-OH-Vit D 127 • Has been taking Vit D 5000 IU daily for “years”

  25. Case 4 • 82 Y of with HTN, endometrial Ca, COPD, morbid obesity p/w inability to walk and b/l knee pain • Ca 16.9 • PTH 7.7 • Cr 1.6 (taking NSAIDs), Hgb 10.6 • 25-OH-Vit D 27.2, 1,25-OH2-Vit D < 8 • SPEP: + M spike – serum free lambda >12,000 • Bone survey: lucency in calvarium, b/l femur and humerus • Rx with IV hydration and steroids (semi-chemo)

More Related